Citation | Zehnder, L; Bennett, M; Meng, J; Huang, B; Ninkovic, S; Wang, F; Braganza, J; Tatlock, J; Jewell, T; Zhou, JZ; Burke, B; Wang, J; Maegley, K; Mehta, PP; Yin, MJ; Gajiwala, KS; Hickey, MJ; Yamazaki, S; Smith, E; Kang, P; Sistla, A; Dovalsantos, E; Gehring, MR; Kania, R; Wythes, M; Kung, PP Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyr J Med Chem54:3368-85 (2011) [PubMed] Article |
---|
SMILES | Nc1nc2CN(Cc2c(n1)-c1c(Cl)cc(Cl)cc1OCCc1ccccn1)C(=O)NC1CCC1 |(4.17,-36.7,;5.5,-35.93,;5.5,-34.39,;6.83,-33.62,;7.15,-32.11,;8.67,-31.94,;9.3,-33.35,;8.17,-34.38,;8.17,-35.93,;6.84,-36.7,;9.5,-36.7,;9.5,-38.24,;8.17,-39.01,;10.83,-39.01,;12.17,-38.23,;13.5,-39,;12.16,-36.69,;10.83,-35.93,;10.82,-34.39,;12.15,-33.61,;13.49,-34.37,;14.82,-33.6,;14.8,-32.07,;16.13,-31.29,;17.47,-32.05,;17.48,-33.59,;16.15,-34.37,;9.44,-30.61,;8.66,-29.28,;10.98,-30.6,;11.74,-29.26,;13.22,-28.86,;12.82,-27.38,;11.33,-27.78,)| |